Rheumatoid ArthritisREMEDIANCT05413759
RhEumatoid Arthritis MEDIcation Adherence
A study testing Pharmaceutical care in multiprofessional collaboration in people with Rheumatoid Arthritis, run by Hospices Civils de Lyon at 2 sites in France.
Trial summary
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Pharmaceutical care in multiprofessional collaboration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 2 sitesFrance
- Study dates
- 28 Jun 2022to 28 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient with diagnosed rheumatoid arthritis (RA),
- Patient, male or female, aged 18 or over,
- Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge
- Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),
- Autonomous patient in the management of his drug treatment,
- Patient understanding and speaking French,
- Patient affiliated to the French general national health insurance or similar,
- Patient having given his free, informed and signed consent.
Who cannot join
- Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study,
- Patient whose regular pharmacy is currently treating another patient.
- Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator),
- Patient whose management of his drug treatment at home is carried out exclusively by a carer,
- Patient participating in another research that may interfere (investigator's judgement) with the results of the present study,
- Adult patient protected under the terms of the law (Public Health Code),
- Patient not fit to carry out the follow-up, according to the judgment of the investigator,
- Pregnant or breastfeeding women.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France2 sites, 2 recruiting
- Recruiting
Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot
Lyon, 69003
Roland CHAPURLAT, MD/PHD, 04 72 11 74 82 ext. +33, roland.charpulat@chu-lyon.fr
Audrey JANOLY-DUMENIL, PharmD, 04 72 11 91 82 ext. +33, audrey.janoly-dumenil@chu-lyon.fr
- Not yet recruiting
Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon
Pierre-Bénite, Lyon, 69495
Charline ESTUBLIER, MD, 04.78.86.65.63 ext. +33, charline.estublier@chu-lyon.fr
Charline ESTUBLIER, MD
About this study
Official title: Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients.
Main objective:
Read more
To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration.
Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)).
METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Pharmaceutical care in multiprofessional collaboration
- Keywords
- medication adherence, rheumatoid arthritis, pharmaceutical care
- Medical subject headings
- Arthritis, Rheumatoid, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmaceutical care in multiprofessional collaborationOther
In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).
Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.
Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.
Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment.
| Study group | Role | What they receive |
|---|---|---|
| Pharmaceutical care in multiprofessional collaboration | Experimental | Medication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion). Receives: Other: Pharmaceutical care in multiprofessional collaboration |
| Control group (usual practices group) | No intervention | Usual follow-up during the 12-month follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication adherence to rheumatoid arthritis treatment
The primary endpoint is the rate of adherent patients to DMARDs after 12 months of follow-up assessed by the Medication Possession Ratio (MPR).
The MPR is calculated for each drug: total quantity of dose units dispensed compared to the theoretical quantity of dose units necessary for compliance with the prescribed dosage. The calculation will be made from:
- dispensing data collected from the patient's community pharmacist (control and intervention group),
- prescription data from all prescriptions (between Month 0 and Month 12), reported by the patient during the visit to Month 12,
- and hospitalization data from the medicalized information system program (PMSI:) and the patient log.
A patient is considered adherent to his treatment if the MPR is greater than or equal to 80%. For patients with more than one DMARD drug prescribed, they will be considered adherent if the MPR of each DMARD is greater than or equal to 80%.
Measured: Month 12
Secondary outcomes (14)
Clinical criteria - Evolution of the Disease Activity Score DAS28
A Disease Activity Score (DAS) indicates the severity of rheumatoid arthritis disease activity at a given moment in time. It is calculated based on several different factors, including lab results, patient feedback, and joint swelling and tenderness.
A traditional DAS score requires examining 44 specific joints.
The DAS28 score is arrived at using:
The number of swollen joints (out of the 28), The number of tender joints (out of the 28), The C reactive protein (CRP) or erythrocyte sedimentation rate (ESR) lab test results Answers to a patient health assessment questionnaire A mathematical formula is used to calculate the overall score. DAS28 can range from 0 to 9.4.
Generally, a DAS28 score of:
More than 5.1 indicates high disease activity Between 3.2 and 5.1 indicates moderate disease activity Between 2.6 and less than 3.2 indicates low disease activity Lower than 2.6 indicates disease remission
Measured: Day 0 and Month 12
Clinical criteria - Number of Rheumatoid Arthritis-related re-hospitalizations
Number of Rheumatoid Arthritis-related re-hospitalizations between Month 0 and Month 12
Measured: Month 0 and Month 12
Clinical criteria - Number of adverse effects related to drug treatments leading to hospitalization.
Number of adverse effects related to drug treatments leading to hospitalization between Month 0 and Month 12.
Measured: Month 0 and Month 12
Functional and quality of life criteria - Evolution of the Health Assessment Questionnaire (HAQ) score
The Evolution of the Health Assessment Questionnaire (HAQ) is an 24-item questionnaire.
Each question is assigned the following score:
0 = without any difficulty ; 1 = with some difficulty ; 2 = with great difficulty ; 3 = unable to do so The rating for each of the 8 domains is the one corresponding to the highest score for the questions in that domain.
The notion of need for help from a third person and/or use of devices can modify this rating system. In this case, the score for the area concerned must be at least equal to 2.
The functional index is the sum of the ratings of the various domains divided by the number of domains evaluated (normally 8, but less in case of totally missing data for a particular domain).
The score obtained is between 0 and 3. The higher the score, the more disabling the pathology.
Measured: Day 0 and Month 12
Functional and quality of life criteria - Evolution of the EuroQol 5-Dimensional score (EQ-5D)
The EuroQol 5-Dimensional score (EQ-5D) is a standardised measure of health-related quality of life.
The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
The evaluation component requires a patient to record their overall health status using a visual analogue scale (EQ-VAS).
Following assessment the scores from the descriptive component can be reported as a five digit number ranging from 11111 (full health) to 33333/55555 (worst health). A number of methods exist for analysing these five digit profiles. Frequently they are converted to a single utility index using country specific value sets, which can be used in the clinical and economic evaluation of health care as well as in population health surveys.
Measured: Day 0 and Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Medication Possession Ratio for each disease-modifying antirheumatic drug (DMARD)
The Medication Possession Ratio is calculated for each drug: total quantity of dose units dispensed compared to the theoretical quantity of dose units necessary for compliance with the prescribed dosage. The calculation will be made from:
- dispensing data collected from the patient's community pharmacist (control and intervention group),
- prescription data from all prescriptions (between Month 0 and Month 12), reported by the patient during the visit to Month 12,
- and hospitalization data from the medicalized information system program (PMSI:) and the patient log.
Measured: Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Adherent rate according to the Compliance Questionnaire on Rheumatology (CQR)
The Compliance Questionnaire on Rheumatology (CQR) is a 19 item, self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as "low" adhering participants (taking <80% of their medication correctly). The four point Likert answering scale ranges from; "Definitely don't agree" (scored 1) to "Definitely agree" (scored 4) with lower scores indicating lower levels of adherence.
Measured: Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Evolution of the BioSecure score or Knowledge score (Methotrexate and/or anti-JAK)
The BioSecure questionnaire assess self-management skills and knowledge and patient safety under biotherapy. It has 55 questions regarding 24 areas of competence. The final score is between 0 and 100, a high score reflecting better knowledge.
Questionnaire about Methotrexate assess self-management skills and knowledge and patient safety under Methotrexate. It has 7 questions and 1 scenario (to be chosen by the doctor out of 5). One point is awarded for each correct answer (refer to the correction of the questionnaire). Total out of 100: (score x 100)/ 31. The final score is between 0 and 100, a high score reflecting better knowledge.
Questionnaire about anti-JAK assess self-management skills and knowledge and patient safety under anti-JAK. It has 8 questions and 6 scenario. One point is awarded for each correct answer (refer to the correction of the questionnaire). Total out of 100: sum x 1.92. The final score is between 0 and 100, a high score reflecting better knowledge.
Measured: Day 0 and Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Evolution of the Beliefs about Medicines Questionnaire (BMQ) score
The BMQ consists of two five-item scales assessing patients' beliefs about the necessity of prescribed medication for controlling their disease and their concerns about potential adverse consequences of taking it. Respondents indicate their degree of agreement with each statement on a five-point Likert scale, ranging from 1 = strongly disagree to 5 = strongly agree. Scores obtained for individual items within both scales are summed. Thus, total scores for the Necessity and Concerns Scales range from 5 to 25. Higher scores indicate stronger beliefs.
Measured: Day 0 and Month 12
Economic criterion
Costs of managing the two strategies.
Measured: Month 12
Intervention implementation and acceptability criteria - Satisfaction of pharmacists and general practitioners through semi-structured interviews
Satisfaction of pharmacists and general practitioners through semi-structured interviews at Month 12
Measured: Month 12
Intervention implementation and acceptability criteria - Duration of follow-up interviews measured by community pharmacist
Duration of follow-up interviews measured by community pharmacist at Month 2 and Month 6
Measured: Month 2 and Month 6
Intervention implementation and acceptability criteria - Number of patients having benefited from a complete follow-up by the town pharmacist (participation in the 2 scheduled meetings to reinforce medication adherence)
Number of patients having benefited from a complete follow-up by the town pharmacist (participation in the 2 scheduled meetings to reinforce medication adherence)
Measured: Month 12
Intervention implementation and acceptability criteria - Patient satisfaction by questionnaire
Patient satisfaction assessed by a 6_item questionnaire completed by patients in the interventional group.
The 6 items are rated on a 4-dimension Likert-scale : "Not at all satisfied", "Not very satisfied", "Quite satisfied", "Completely satisfied". Answers will be the subject of a descriptive analysis.
Measured: Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2022
- Study start28 Jun 2022
- Primary completion28 Dec 2026 (estimated)
- Study completion28 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Roland CHAPURLAT, MD/PHD, Principal investigator, Hospices Civils de Lyon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05413759
- Sponsor's protocol ID
- 69HCL20_0272
- Acronym
- REMEDIA
- Status last verified
- Sep 2025
- First submitted
- 23 May 2022
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Collaborative Pharmaceutical Care Initiated in Hospital and Continued in Primary Care to Improve Medication Adherence of Patients With Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT05413759
- Acronym / sponsor ID
- REMEDIA / 69HCL20_0272
- Conditions
- Rheumatoid Arthritis
- Keywords
- medication adherence, rheumatoid arthritis, pharmaceutical care
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 28 Jun 2022 (actual)
- Primary completion
- 28 Dec 2026 (estimated)
- Study completion
- 28 Dec 2027 (estimated)
- First posted
- 10 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients.
Main objective:
To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration.
Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)).
METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pharmaceutical care in multiprofessional collaboration | Experimental | Other: Pharmaceutical care in multiprofessional collaborationMedication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion). |
| Control group (usual practices group) | No intervention | –Usual follow-up during the 12-month follow-up. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Patient with diagnosed rheumatoid arthritis (RA),
- Patient, male or female, aged 18 or over,
- Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge
- Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),
- Autonomous patient in the management of his drug treatment,
Key exclusion criteria (8 listed)
- Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study,
- Patient whose regular pharmacy is currently treating another patient.
- Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator),
- Patient whose management of his drug treatment at home is carried out exclusively by a carer,
- Patient participating in another research that may interfere (investigator's judgement) with the results of the present study,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmaceutical care in multiprofessional collaborationIn addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months). Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization. Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills. Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment. | Other | Pharmaceutical care in multiprofessional collaboration |
Primary outcome
Medication adherence to rheumatoid arthritis treatment
Time frame: Month 12
The primary endpoint is the rate of adherent patients to DMARDs after 12 months of follow-up assessed by the Medication Possession Ratio (MPR). The MPR is calculated for each drug: total quantity of dose units dispensed compared to the theoretical quantity of dose units necessary for compliance with the prescribed dosage. The calculation will be made from: * dispensing data collected from the patient's community pharmacist (control and intervention group), * prescription data from all prescriptions (between Month 0 and Month 12), reported by the patient during the visit to Month 12, * and hospitalization data from the medicalized information system program (PMSI:) and the patient log. A patient is considered adherent to his treatment if the MPR is greater than or equal to 80%. For patients with more than one DMARD drug prescribed, they will be considered adherent if the MPR of each DMARD is greater than or equal to 80%.
14 secondary outcomes
Clinical criteria - Evolution of the Disease Activity Score DAS28
Time frame: Day 0 and Month 12
Clinical criteria - Number of Rheumatoid Arthritis-related re-hospitalizations
Time frame: Month 0 and Month 12
Clinical criteria - Number of adverse effects related to drug treatments leading to hospitalization.
Time frame: Month 0 and Month 12
Functional and quality of life criteria - Evolution of the Health Assessment Questionnaire (HAQ) score
Time frame: Day 0 and Month 12
Functional and quality of life criteria - Evolution of the EuroQol 5-Dimensional score (EQ-5D)
Time frame: Day 0 and Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Medication Possession Ratio for each disease-modifying antirheumatic drug (DMARD)
Time frame: Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Adherent rate according to the Compliance Questionnaire on Rheumatology (CQR)
Time frame: Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Evolution of the BioSecure score or Knowledge score (Methotrexate and/or anti-JAK)
Time frame: Day 0 and Month 12
Criteria for patient behavior in relation to their disease-modifying antirheumatic drugs (DMARDs) - Evolution of the Beliefs about Medicines Questionnaire (BMQ) score
Time frame: Day 0 and Month 12
Economic criterion
Time frame: Month 12
Intervention implementation and acceptability criteria - Satisfaction of pharmacists and general practitioners through semi-structured interviews
Time frame: Month 12
Intervention implementation and acceptability criteria - Duration of follow-up interviews measured by community pharmacist
Time frame: Month 2 and Month 6
Intervention implementation and acceptability criteria - Number of patients having benefited from a complete follow-up by the town pharmacist (participation in the 2 scheduled meetings to reinforce medication adherence)
Time frame: Month 12
Intervention implementation and acceptability criteria - Patient satisfaction by questionnaire
Time frame: Month 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Rheumatoid Arthritis
RecruitingPhase 1
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Not yet recruiting
Effects of Paraffin Wax Therapy and Dry Cupping on Pain and Wrist Function in Patients With Rheumatoid Arthritis
Rheumatic Arthritis
RecruitingPhase 2
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Sjogren's Syndrome
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
A Study of AZD0120 in Autoimmune Diseases
Systemic Sclerosis, Idiopathic Inflammatory Myopathies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Roland CHAPURLAT, MD/PHD principal investigator
Hospices Civils de Lyon
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pharmaceutical care in multiprofessional collaboration in people with Rheumatoid Arthritis, run by Hospices Civils de Lyon at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Roland CHAPURLAT, MD/PHD (04 72 11 74 82 ext. +33, roland.charpulat@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication adherence to rheumatoid arthritis treatment (time frame: Month 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.